A.  Personal Statement

I am an Assistant Professor in the Department of Urology and Associate Program Director of the Urologic Oncology Fellowship at the University of Pittsburgh, with clinical and research expertise directly relevant to the proposed study on men with benign prostatic hyperplasia (BPH). I completed my fellowship training in health services research, urologic oncology, and laparoscopy/endourology at the University of Michigan. My research interests include examining urologic treatments and their implications for clinical outcomes and health policy. This background makes me especially well-suited to be a co-investigator on this proposal. Pertaining to BPH specifically, I was involved in the initial U54 proposal, obtained a Shadyside Hospital Foundation grant entitled the “Critical examination of the treatment of benign prostatic hyperplasia (BPH) in men” (see A1 below), and mentored several medical students who were provided research opportunities from the initial U54 proposal. Clinically, I have extensive experience managing patients with BPH, both with medications and surgical treatments. Overall, I look forward to working with the co-investigators on this exciting project.

1. Shah AA, Kumar P, Ogunmola AG, Ayyash O, Yabes JG, Sabik LM, Odisho AY, Bandari J, Macleod LC, Davies BJ, Jacobs BL. Statewide Price Variation for Generic Benign Prostatic Hyperplasia Medications. Urol 2020; Sep 19 [Epub ahead of print].

B.  Positions and Employment

2010-13        Clinical Lecturer, Department of Urology, University of Michigan, Ann Arbor, MI
2013-            Assistant Professor, Department of Urology, University
                     of Pittsburgh, Pittsburgh, PA
2014-            The Center for Research on Health Care faculty member, University of
                     Pittsburgh, Pittsburgh, PA
2018-            Associate Program Director, Urologic Oncology Fellowship, University of
                     Pittsburgh, Pittsburgh, PA

Other Experience and Professional Memberships

2006-            American Urological Association, Candidate Member
2007-            Endourological Society
2011-            Society of Urologic Oncology, Candidate Member
2012-            American Society of Clinical Oncology
2013-            AcademyHealth Member
2014-            Member of the Via Pathways Physician Advisory Committee-Surgical Oncology
                     Renal Committee Co-Chair
2014-            Health Services Research Data Center Advisory Committee
2013-16        American Society of Clinical Oncology Cancer Education Committee
2015              Appropriateness of using indwelling urinary catheters in surgery patients-
                      Expert Panel
2015              Anticoagulation Consortium Roundtable-Expert Panel
2015-16        American Society of Clinical Oncology Cancer Education Committee
                     Track Leader

Honors

2008              American Urological Association Gerald P. Murphy Scholar
2012              Silbar Traveling Fellowship Award, North Central Section American Urological
                      Annual Meeting
2013              Urologic Diseases in America Request for Individual Research Proposals,
                      recipient
2013              Aspen Cancer Conference Fellow—selected based on work supported by
                      American Cancer Society Postdoctoral Fellowship Grant
2014              Dennis W. Jahnigen Career Development Award--$25,000 for two years as
                      a supplement to the Grants for Early Medical/Surgical Specialists’
                      Transition to Aging Research (GEMSSTAR) award
2014              Tippins Foundation Scholar Award—$25,000 award applied to prostate
                      cancer research
2018              Resident Teaching Award, Department of Urology, University of Pittsburgh
2019              Tippins Foundation Scholar Award—$25,000 award applied to health services
                      research

C. Contribution to Science

1. Improved characterization of adoption of new technologies for prostate cancer treatment. Many new technologies have been adopted for the treatment of prostate cancer over the last several years. One of my research interests is to improve the characterization of this adoption.

1a. Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Schroeck FR, Bekelman JE, Kahn JM, Nelson JB, Barnato AE. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer. Cancer 2017; 123(15): 294. PubMed PMCID:PMC5517344.

1b. Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, Gilbert SM, Strope SA, Dunn RL, Miller DC, Hollenbeck BK. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. Journal of the American Medical Association 2013; 309(24): 2587-2595. PubMed PMCID:PMC3857348.

1c. Jacobs BL, Zhang Y, Skolarus TA, Hollenbeck BK. Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Affairs 2012; 31(4): 750-759. PubMed PMCID:PMC3500551.

1d. Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Miller DC, Hollenbeck BK. Comparative effectiveness of external-beam radiation approaches for prostate cancer. European Urology 2014; 65(1): 162-168. PubMed PMCID:PMC4128498.

2. Improved understanding of relationships among health care organizations, health regulations, and the adoption of new technologies. The relationship among health care organizations, health regulations, and the adoption of new technologies is largely unknown. My research has helped to better understand this relationship.

2a. Jacobs BL, Sunderland R, Yabes J, Nelson JB, Barnato AE, Bekelman JE. Local coverage determination policy and the use of stereotactic body radiation therapy for prostate cancer. Urology Practice 2015; 2(6): 304-311. PubMed PMID: 27493987; PMCID: PMC4968880.

2b. Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK. Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer. Urology 2012; 80(6): 1236- 1242. PMCID:PMC3514877.

2c. Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK. Certificate of need legislation and the dissemination of robotic surgery for prostate cancer. The Journal of Urology 2013; 189(1): 80-85. PubMed PMID: 23164388.

2d. Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK. Certificate of need regulations and the diffusion of intensity-modulated radiotherapy. Urology 2012; 80(5): 1015- 1020. PubMed PMCID:PMC3505690.

3. Improved characterization of readmissions after major surgery to help prevent hospital readmissions. Preventing hospital readmissions is a major priority of our health care system. I have been actively involved in better characterizing readmissions after major surgery.

3a. Krishnan N, Liu X, Lavieri MS, Hu M, Helfand A, Benjamin L, Helm JE, He C, Hollenbeck BK, Skolarus TA, Jacobs BL. A model to optimize follow-up care and reduce hospital readmissions after radical cystectomy. The Journal of Urology 2016; 195(5): 1367. PubMed PMID: 26682758.

3b. Skolarus TA, Jacobs BL, Schroeck FR, He C, Helfand AM, Helm J, Hu M, Lavieri M, Hollenbeck BK. Understanding hospital readmission intensity after radical cystectomy. The Journal of Urology 2015; 193(5): 1500-1506. PubMed PMID: 25451833.

3c. Hu M, Jacobs BL, Montgomery JS, He C, Ye J, Zhang Y, Brathwaite J, Morgan TM, Hafez KS, Weizer AZ, Gilbert SM, Lee CT, Lavieri MS, Helm JE, Hollenbeck BK, Skolarus TA. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer 2014; 120(9): 1409-1416. PubMed PMID: 24477968.

3d. Jacobs BL, Zhang Y, Tan HJ, Ye Z, Skolarus TA, Hollenbeck BK. Hospitalization trends after prostate and bladder surgery: implications of potential payment reforms. The Journal of Urology 2013; 189(1): 59-65. PubMed PMID: 23164391.

4. Improved characterization of quality of care measures in prostate cancer patients in support of growing emphasis on quality over quantity of health care. There is a growing emphasis on quality as opposed to quantity of health care. I have been actively involved in improving the characterization of quality of care measures in prostate cancer patients.

4a. Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Montgomery JS, Weizer AZ, Hollenbeck BK. Adherence to performance measures and outcomes among men treated for prostate cancer. The Journal of Urology 2014; 192(3): 743-748. PubMed PMID:  24681332; PMCID:PMC4143464; NIHMS:577063.

4b. Schroeck FR, Kaufman SR, Jacobs BL, Hollenbeck BK. Receipt of "Best Care" according to current quality of care measures and outcomes among men with prostate cancer. The Journal of Urology 2015; 193(2): 500-504. PubMed PMID: 25108275; PMCID:PMC4305472; NIHMS619638.

4c. Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Hollingsworth JM, Shahinian VB, Hollenbeck BK. Regional variation in quality of prostate cancer care. The Journal of Urology 2014; 191(4): 957-962. PubMed PMID: 24144685; PMCID:PMC3980045; NIHMS533337.

4d. Schroeck FR, Jacobs BL, Hollenbeck BK. Understanding variation in the quality of the surgical treatment of prostate cancer. American Society of Clinical Oncology Educational Book 2013; 278-283.  PubMed PMID: 23714522; PMCID:PMC7010404.

5. Improved understand of the influence of networks of hospitals and physicians on care delivery. Patterns of health care delivery are complex. I have been actively involved in examining how networks of hospitals and their physicians impact patterns of care.

5a. Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CC, Bekelman JE, Nelson JB, Bynum JPW, Barnato AE, Kahn JM. The development and validation of prostate cancer-specific physician-hospital networks. Urol 2020; 2020; 138: 37-44. PubMed PMID: 31945379; PMCID:7141943.

5b. Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CC, Bekelman JE, Nelson JB, Bynum JPW, Barnato AE, Kahn JM. Patterns of stereotactic body radiation therapy: the influence of lung cancer treatment on prostate cancer treatment. Urol Onc 2020; 38(2): 37.e21-37.e27. PubMed PMID: 31699490; PMCID:PMC6954961.

5c. Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Bekelman JE, Nelson JB, Bynum JPW, Barnato AE, Kahn JM. The influence of stereotactic body radiation therapy adoption on prostate cancer treatment patterns. J Urol 2020; 203(1): 128-136. PubMed PMID: 31361571; PMCID:PMC7946357.

Completed List of Published Work in MyBibliography:

https://www.ncbi.nlm.nih.gov/sites/myncbi/1dkc9b-c-z-5s/bibliography/478...